Clinical Trial Update: Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting efficacy and safety data for nemolizumab in adults with moderate-to-severe atopic dermatitis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Nemolizumab (nemolizumab)

Snippet

Sponsor: Galderma R&D | Conditions: Moderate-to-Severe Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2024-08-14